CN104363909A - 法哌酯用于治疗注意力缺陷多动症的用途 - Google Patents
法哌酯用于治疗注意力缺陷多动症的用途 Download PDFInfo
- Publication number
- CN104363909A CN104363909A CN201280067749.7A CN201280067749A CN104363909A CN 104363909 A CN104363909 A CN 104363909A CN 201280067749 A CN201280067749 A CN 201280067749A CN 104363909 A CN104363909 A CN 104363909A
- Authority
- CN
- China
- Prior art keywords
- ester
- phenyl
- pharmaceutically acceptable
- piperidin
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *N(CCCC1)[C@]1[C@](c1ccccc1)O Chemical compound *N(CCCC1)[C@]1[C@](c1ccccc1)O 0.000 description 3
- BKPLVPRTTWIDNL-ZIAGYGMSSA-N CC(O[C@@H]([C@@H]1NCCCC1)c1ccccc1)=O Chemical compound CC(O[C@@H]([C@@H]1NCCCC1)c1ccccc1)=O BKPLVPRTTWIDNL-ZIAGYGMSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1160902 | 2011-11-29 | ||
FR1160902A FR2983197B1 (fr) | 2011-11-29 | 2011-11-29 | Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite |
PCT/FR2012/052749 WO2013079873A1 (fr) | 2011-11-29 | 2012-11-29 | Phacetoperane pour traiter un trouble deficit de l'attention hyperactivite |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104363909A true CN104363909A (zh) | 2015-02-18 |
CN104363909B CN104363909B (zh) | 2017-12-15 |
Family
ID=47436090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280067749.7A Active CN104363909B (zh) | 2011-11-29 | 2012-11-29 | 法哌酯用于治疗注意力缺陷多动症的用途 |
Country Status (19)
Country | Link |
---|---|
US (4) | US20150038533A1 (zh) |
EP (2) | EP2785344B1 (zh) |
JP (2) | JP6143112B2 (zh) |
CN (1) | CN104363909B (zh) |
CA (1) | CA2856701C (zh) |
CY (1) | CY1118537T1 (zh) |
DK (1) | DK2785344T3 (zh) |
ES (2) | ES2610563T3 (zh) |
FR (1) | FR2983197B1 (zh) |
HR (1) | HRP20161776T1 (zh) |
HU (1) | HUE030575T2 (zh) |
IL (1) | IL232897B (zh) |
LT (1) | LT2785344T (zh) |
PL (1) | PL2785344T3 (zh) |
PT (1) | PT2785344T (zh) |
RS (1) | RS55523B1 (zh) |
SI (1) | SI2785344T1 (zh) |
SM (1) | SMT201600466B (zh) |
WO (1) | WO2013079873A1 (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2928835A (en) * | 1959-02-19 | 1960-03-15 | Rhone Poulenc Sa | New esters |
US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2838739B1 (fr) * | 2002-04-19 | 2004-05-28 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique |
FR2842804B1 (fr) * | 2002-07-29 | 2004-09-03 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
FR2861074B1 (fr) * | 2003-10-17 | 2006-04-07 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
-
2011
- 2011-11-29 FR FR1160902A patent/FR2983197B1/fr active Active
-
2012
- 2012-11-29 WO PCT/FR2012/052749 patent/WO2013079873A1/fr active Application Filing
- 2012-11-29 HU HUE12806593A patent/HUE030575T2/en unknown
- 2012-11-29 ES ES12806593.5T patent/ES2610563T3/es active Active
- 2012-11-29 US US14/360,355 patent/US20150038533A1/en not_active Abandoned
- 2012-11-29 CA CA2856701A patent/CA2856701C/fr active Active
- 2012-11-29 ES ES16195856T patent/ES2792875T3/es active Active
- 2012-11-29 CN CN201280067749.7A patent/CN104363909B/zh active Active
- 2012-11-29 EP EP12806593.5A patent/EP2785344B1/fr active Active
- 2012-11-29 DK DK12806593.5T patent/DK2785344T3/en active
- 2012-11-29 RS RS20161156A patent/RS55523B1/sr unknown
- 2012-11-29 JP JP2014543958A patent/JP6143112B2/ja active Active
- 2012-11-29 PT PT128065935T patent/PT2785344T/pt unknown
- 2012-11-29 EP EP16195856.6A patent/EP3153168B1/fr active Active
- 2012-11-29 PL PL12806593T patent/PL2785344T3/pl unknown
- 2012-11-29 SI SI201230833A patent/SI2785344T1/sl unknown
- 2012-11-29 LT LTEP12806593.5T patent/LT2785344T/lt unknown
-
2014
- 2014-05-29 IL IL232897A patent/IL232897B/en active IP Right Grant
-
2016
- 2016-12-22 SM SM201600466T patent/SMT201600466B/it unknown
- 2016-12-23 HR HRP20161776TT patent/HRP20161776T1/hr unknown
- 2016-12-30 CY CY20161101361T patent/CY1118537T1/el unknown
-
2017
- 2017-04-26 JP JP2017086964A patent/JP2017149763A/ja active Pending
-
2018
- 2018-03-06 US US15/913,481 patent/US10456387B2/en not_active Expired - Fee Related
-
2019
- 2019-09-17 US US16/573,493 patent/US20200061044A1/en not_active Abandoned
-
2021
- 2021-11-08 US US17/521,010 patent/US20220054471A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2928835A (en) * | 1959-02-19 | 1960-03-15 | Rhone Poulenc Sa | New esters |
US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
Also Published As
Publication number | Publication date |
---|---|
RS55523B1 (sr) | 2017-05-31 |
HUE030575T2 (en) | 2017-05-29 |
US20200061044A1 (en) | 2020-02-27 |
FR2983197A1 (fr) | 2013-05-31 |
JP2017149763A (ja) | 2017-08-31 |
LT2785344T (lt) | 2017-04-25 |
US20150038533A1 (en) | 2015-02-05 |
EP2785344A1 (fr) | 2014-10-08 |
US10456387B2 (en) | 2019-10-29 |
ES2792875T3 (es) | 2020-11-12 |
EP3153168A1 (fr) | 2017-04-12 |
IL232897B (en) | 2019-02-28 |
PT2785344T (pt) | 2017-01-18 |
CA2856701A1 (fr) | 2013-06-06 |
PL2785344T3 (pl) | 2017-06-30 |
ES2610563T3 (es) | 2017-04-28 |
HRP20161776T1 (hr) | 2017-03-10 |
DK2785344T3 (en) | 2017-01-23 |
SI2785344T1 (sl) | 2017-04-26 |
JP6143112B2 (ja) | 2017-06-07 |
CY1118537T1 (el) | 2017-07-12 |
JP2014533742A (ja) | 2014-12-15 |
US20220054471A1 (en) | 2022-02-24 |
SMT201600466B (it) | 2017-03-08 |
EP3153168B1 (fr) | 2020-02-26 |
CN104363909B (zh) | 2017-12-15 |
WO2013079873A1 (fr) | 2013-06-06 |
CA2856701C (fr) | 2020-07-28 |
US20180214436A1 (en) | 2018-08-02 |
IL232897A0 (en) | 2014-07-31 |
FR2983197B1 (fr) | 2014-07-25 |
EP2785344B1 (fr) | 2016-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106831541B (zh) | 毒蕈碱性m1受体激动剂 | |
RU2409365C2 (ru) | ПРИМЕНЕНИЕ 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА ДЛЯ ЛЕЧЕНИЯ СИМПТОМОВ БОЛЕЗНИ ГЕНТИНГТОНА | |
US20090105338A1 (en) | Deuterium-enriched gabexate mesylate | |
UA81186C2 (en) | N-heterocyclylmethyl benzamide derivatives, preparation thereof and use in therapy | |
PT1680418E (pt) | Derivados de n-[heteroaril ( piperidin-2-il)-metil] benzamida, sua preparação e sua aplicação em terapêutica | |
ES2609264T3 (es) | Formas sólidas que comprenden (-)-O-desmetilvenlafaxina y usos de las mismas | |
KR20220131520A (ko) | 아릴시클로헥실아민 유도체 및 정신장애 치료에서의 이의 용도 | |
CN110678205A (zh) | 治疗精神分裂症的方法 | |
NO178105B (no) | Tramadol-N-oksydmateriale, enantiomerer og preparater derav | |
CN105431432A (zh) | 奎宁类化合物、其光学异构体及其制备方法和医药用途 | |
CN100418525C (zh) | 对钙通道α-2-δ亚基具有亲合力的脯氨酸衍生物 | |
KR20200003791A (ko) | 듀테트라베나진의 유사체, 이의 제조 및 용도 | |
CN104363909A (zh) | 法哌酯用于治疗注意力缺陷多动症的用途 | |
CN101415410B (zh) | 安非他酮代谢物用于制备治疗炎性病症的药物的用途 | |
TW200916092A (en) | N-oxides of venlafaxine and O-desmethylvenlafaxine as prodrugs | |
JP2020526592A (ja) | シクロベンザプリン類似体及びアミトリプチレン類似体 | |
JPH0395143A (ja) | アミノケトン誘導体 | |
WO2008157271A1 (en) | Deuterium-enriched escitalopram | |
CN107200725A (zh) | 稠杂环类衍生物、其制备方法及其在医药上的应用 | |
CA2620418A1 (en) | Benztropine compounds and uses thereof | |
CN101267820A (zh) | 新颖氮杂双环[3.2.1]辛-2-烯衍生物及其作为单胺神经递质再摄取抑制剂的用途 | |
PT98556B (pt) | Processo para a preparacao do acido (s)(+)-2-etoxi-4-{1-(2-piperidino-fenil-1-butil)-aminocarbonilmetil}-benzoico e de composicoes farmaceuticas que os contem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180326 Address after: Swiss Stans Patentee after: NLS pharmaceutical JSC Address before: Swiss Stans Patentee before: NLS-1 pharmaceutical JSC Effective date of registration: 20180326 Address after: Swiss Stans Patentee after: NLS-1 pharmaceutical JSC Address before: Paris France Patentee before: Public Relief Agency-Paris Hospital |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220520 Address after: Zurich, SUI Patentee after: NLS pharmacy Co.,Ltd. Address before: Swiss Stans Patentee before: NLS pharmaceutical JSC |